The extracellular matrix on atherogenesis and diabetes-associated vascular disease.
Atherosclerosis is remarkably increased in type 2 diabetes suggesting that mechanisms causing arterial lesion are enhanced by the metabolic disturbances of insulin resistance (IR) and diabetes. Several lines of research suggest that processes taking place in the arterial intima extracellular matrix may be part of a shared pathogenic mechanism. The intima extracellular matrix is where atherogenesis takes place. This layer contains fibrilar macromolecules like collagens, proteoglycans (PGs), hyaluronate, and extracellular multi-domain proteins. Specific interaction of lysine, arginine-rich segments of the apoB-100 lipoproteins, LDL, IDL and Lp (a), with the negatively charged glycosaminoglycans (GAGs) of PGs cause retention of the lipoproteins, one of the initiation process of atherogenesis. Such interactions cause structural modifications of the lipid and protein moieties of the lipoproteins that appear to increase their susceptibility to proteases, phospholipases and free radical-mediated processes. The association of apoB-lipoproteins, specially small and dense LDL, with intima PGs increases their uptake by macrophages and human arterial smooth muscle cells (HASMC) leading to 'foam cell' formation. In vitro, elevated levels of non-esterified fatty acids (NEFA) alter the matrix of endothelial cells basement membrane making them more permeable to macromolecules. NEFA cause changes in the expression of genes controlling the PGs composition of the PGs secreted by HASMC causing formation of a matrix with high affinity for LDL. These results lead us to speculate that an important component of the dyslipidemia of IR and type 2 diabetes, chronic high NEFA, may contribute to cellular alterations that cause changes of the arterial intima extracellular matrix. Such changes may increase the atherogenicity of the retention of apoB lipoproteins in the intima and contribute to the systemic alteration of the arterial wall frequently observed in IR and type 2 diabetes.
Camejo
Germán
G
Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska University Hospital, Gothenberg, Sweden.
Olsson
Urban
U
Hurt-Camejo
Eva
E
Baharamian
Nahid
N
Bondjers
Göran
G
D001161:Arteriosclerosis / Q000209:etiology* / Q000378:metabolism; D008078:Cholesterol, LDL / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000378:metabolism; D005109:Extracellular Matrix / Q000378:metabolism*; D005230:Fatty Acids, Nonesterified / Q000378:metabolism*; D006801:Humans; D006949:Hyperlipidemias / Q000503:physiopathology*; D007333:Insulin Resistance / Q000502:physiology; D008264:Macrophages / Q000378:metabolism*; D011453:Prostaglandins / Q000378:metabolism*; D017539:Tunica Intima / Q000473:pathology*
D008078:Cholesterol, LDL; D005230:Fatty Acids, Nonesterified; D011453:Prostaglandins